<DOC>
	<DOCNO>NCT02485548</DOCNO>
	<brief_summary>This study multicenter phase Ⅲ trial . The objective compare efficacy toxicity cisplatin plus raltitrexed 5-fluorouracil concurrence IMRT patient locoregionally advanced head neck squamous cell cancer .</brief_summary>
	<brief_title>Cisplatin Plus Raltitrexed 5-fluorouracil Concurrent With Radiotherapy Head Neck Squamous Cell Cancer</brief_title>
	<detailed_description>The objective compare efficacy toxicity cisplatin plus raltitrexed 5-fluorouracil concurrence IMRT patient locoregionally advanced head neck squamous cell cancer .</detailed_description>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Pathologically confirm untreated head neck squamous cell cancer patient 1870 year Clinical stage : T34N03M0 T14N13M0 Hematologic function : WBC ≥ 4.0×109/L , PLT ≥ 80×109/L , Hb ≥ 10mg/dL Renal function : Cr ≤ 1.25×UNL Hepatic function : BIL ≤ 1.5×UNL , ALT/AST ≤ 2.5×UNL ECOG ≤ 1 Woman man childbearing age must adopt contraception With write consent Malignant history Pregnant lactate woman With severe disease ( blood , liver , kidney heart disease ) Subjects suitable chemoradiotherapy Without write consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>